Genovis AB (publ.) (GENO) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.059x

Based on the latest financial reports, Genovis AB (publ.) (GENO) has a cash flow conversion efficiency ratio of 0.059x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr15.90 Million ≈ $1.71 Million USD) by net assets (Skr271.52 Million ≈ $29.22 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Genovis AB (publ.) - Cash Flow Conversion Efficiency Trend (2008–2025)

This chart illustrates how Genovis AB (publ.)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Genovis AB (publ.) for a breakdown of total debt and financial obligations.

Genovis AB (publ.) Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Genovis AB (publ.) ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Fabasoft AG
XETRA:FAA
0.034x
Cj Corp Pref 
KO:001045
0.099x
Friedman Industries Inc. Common Stock
NASDAQ:FRD
0.003x
Wam Alternative Assets Ltd
AU:WMA
-0.026x
Harbin Bank Co. Ltd
F:5H6
-1.253x
Federal Agricultural Mortgage Corporation
NYSE:AGM-A
0.060x
First Farms A/S
CO:FFARMS
-0.033x
Kelly Partners Group Holdings Ltd
AU:KPG
0.259x

Annual Cash Flow Conversion Efficiency for Genovis AB (publ.) (2008–2025)

The table below shows the annual cash flow conversion efficiency of Genovis AB (publ.) from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Genovis AB (publ.) worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 Skr271.52 Million
≈ $29.22 Million
Skr32.02 Million
≈ $3.45 Million
0.118x -27.56%
2024-12-31 Skr227.97 Million
≈ $24.53 Million
Skr37.12 Million
≈ $3.99 Million
0.163x -54.15%
2023-12-31 Skr190.81 Million
≈ $20.53 Million
Skr67.75 Million
≈ $7.29 Million
0.355x +4908.05%
2022-12-31 Skr125.65 Million
≈ $13.52 Million
Skr-927.95K
≈ $-99.86K
-0.007x -101.83%
2021-12-31 Skr113.99 Million
≈ $12.27 Million
Skr45.92 Million
≈ $4.94 Million
0.403x +835.02%
2020-12-31 Skr87.17 Million
≈ $9.38 Million
Skr3.76 Million
≈ $404.12K
0.043x -88.31%
2019-12-31 Skr35.62 Million
≈ $3.83 Million
Skr13.13 Million
≈ $1.41 Million
0.368x +868.80%
2018-12-31 Skr26.07 Million
≈ $2.81 Million
Skr-1.25 Million
≈ $-134.48K
-0.048x +89.57%
2017-12-31 Skr18.19 Million
≈ $1.96 Million
Skr-8.36 Million
≈ $-899.14K
-0.459x +55.57%
2016-12-31 Skr15.55 Million
≈ $1.67 Million
Skr-16.08 Million
≈ $-1.73 Million
-1.034x +43.40%
2015-12-31 Skr8.82 Million
≈ $949.39K
Skr-16.12 Million
≈ $-1.73 Million
-1.827x -20.06%
2014-12-31 Skr14.58 Million
≈ $1.57 Million
Skr-22.19 Million
≈ $-2.39 Million
-1.522x -303.82%
2013-12-31 Skr33.09 Million
≈ $3.56 Million
Skr-12.47 Million
≈ $-1.34 Million
-0.377x +65.40%
2012-12-31 Skr13.63 Million
≈ $1.47 Million
Skr-14.85 Million
≈ $-1.60 Million
-1.089x -61.46%
2011-12-31 Skr18.01 Million
≈ $1.94 Million
Skr-12.15 Million
≈ $-1.31 Million
-0.675x +2.00%
2010-12-31 Skr15.23 Million
≈ $1.64 Million
Skr-10.48 Million
≈ $-1.13 Million
-0.688x +45.43%
2009-12-31 Skr10.86 Million
≈ $1.17 Million
Skr-13.70 Million
≈ $-1.47 Million
-1.261x +49.75%
2008-12-31 Skr6.68 Million
≈ $718.56K
Skr-16.76 Million
≈ $-1.80 Million
-2.510x --

About Genovis AB (publ.)

ST:GENO Sweden Biotechnology
Market Cap
$137.92 Million
Skr1.28 Billion SEK
Market Cap Rank
#17956 Global
#306 in Sweden
Share Price
Skr19.40
Change (1 day)
+2.54%
52-Week Range
Skr16.16 - Skr29.50
All Time High
Skr87.00
About

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an… Read more